2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. (MRK) based on the provided data, presented in a structured format:

**1) Return Rate Comparison & Alpha/Beta Analysis:**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets medicines, vaccines, and animal health products.
*   **Return Comparison:**
    *   MRK Cumulative Return: 21.74%
    *   S&P 500 (VOO) Cumulative Return: 91.40%
    *   Divergence: -83.3 (Relative Divergence: 21.7)
*   **Analysis:** MRK has significantly underperformed the S&P 500 over the analyzed period. The relative divergence of 21.7 suggests that the current divergence is near the lower end of its historical range compared to the S\&P 500.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 25.0% | 99.5% | 22.0% | 0.7 | 182.1 |
| 2017-2019  | 37.0% | 99.2% | 20.0% | 0.7 | 216.8 |
| 2018-2020  | 13.0% | 98.0% | -8.0% | 0.7 | 195.0 |
| 2019-2021  | 0.0% | 87.0% | -43.0% | 0.6 | 191.4 |
| 2020-2022  | 14.0% | 84.0% | 16.0% | 0.5 | 277.1 |
| 2021-2023  | 31.0% | 54.3% | 30.0% | 0.3 | 272.3 |
| 2022-2024  | -5.0% | 73.7% | -24.0% | 0.3 | 248.5 |
| 2023-2025  | -24.0% | 100.0% | -86.0% | 0.3 | 262.9 |

*   **Alpha/Beta Analysis:**
    *   **Alpha:** The Alpha values show a fluctuating trend, indicating periods of both outperformance and underperformance relative to the market. The recent negative Alpha values, especially -86% for 2023-2025, suggest significant underperformance.
    *   **Beta:** The Beta values are consistently below 1, indicating that MRK has historically been less volatile than the overall market (S&P 500). The recent Beta of 0.3 indicates even lower volatility.
    *   **CAGR & MDD:** The table reveals a decline in CAGR over the recent periods, coupled with high MDD (Maximum Drawdown), indicating substantial potential losses from peak to trough.
    *   **Capitalization:** The company's capitalization (Cap) has generally been increasing.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 105.26
*   **Previous Close:** 106.06
*   **Change:** -0.75
*   **5-day SMA:** 106.234
*   **20-day SMA:** 101.8025
*   **60-day SMA:** 94.1685

*   **Analysis:** The stock price experienced a slight decrease, falling below the 5-day SMA. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, suggesting an upward trend in the short to medium term. The small negative change suggests a relatively stable stock price.

**3) RSI, PPO, and Divergence Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (Medium to High Investment Recommendation)
*   **RSI:** 75.92 (Overbought)
*   **PPO:** 0.1233
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) Relative Divergence Change:** 1.7 (+) (Short-term increase)
*   **Expected Return (%):** 0.0 (Neutral)

*   **Analysis:**
    *   **MRI:** The MRI suggests a medium to high investment recommendation.
    *   **RSI:** An RSI above 70 indicates an overbought condition, which might suggest a potential pullback in the near term.
    *   **PPO:** PPO measures the percentage of difference between the two moving averages.
    *   **Hybrid Signal:** The hybrid signal recommends investing 100% of cash, indicating a potentially favorable investment opportunity.
    *   **Divergence:** The recent increase in relative divergence indicates a short-term positive trend.
    *   **Expected Return:** The expected return of 0% indicates a neutral outlook for long-term investment relative to the S&P 500.
    *   **Recent Price Change:** The {'price': 105.26, 'previousClose': 106.06, 'change': -0.75} reflects a recent minor price decline.

**4) Recent News & Significant Events:**

*   **[2025-12-16]** Morgan Stanley lifted the price target for Merck, indicating a positive outlook for the biopharma sector.
*   **[2026-01-02]** A news report mentions Merck stock slipping due to the New Year holiday, focusing on what investors should watch next.
*   **[2026-01-01]** Seeking Alpha published an article titled "Merck: Framework For Success," suggesting a positive outlook for the company.
*   **[2026-01-01]** Northwest Capital Management Inc. sold shares of Merck, which could indicate a change in their investment strategy or profit-taking.
*   **[2025-12-30]** An article compares Merck's stock against its peers.
*   **[2025-11-26]** Forbes reports on why Merck stock was surging, which is a positive indicator.

*   **Analysis:** The news is mixed. Analyst upgrades and positive articles like "Framework For Success" are bullish. Share sales by Northwest Capital could be a slight concern. The overall sentiment seems moderately positive, focusing on the company's potential and biopharma outlook.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.90)
*   **Opinions:** 26
*   **Target Price:** Avg: 110.04 / High: 139.00 / Low: 83.00
*   **Recent Rating Changes:** No specific recent changes indicated (blank).

*   **Analysis:** The analyst consensus is "Buy," indicating a generally positive outlook. The average target price of $110.04 suggests potential upside from the current price of $105.26.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-11-05 | 2.32 | 17.28 B$     |
| 2025-08-05 | 1.76 | 15.81 B$     |
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2025-11-05 | 1.25 | 16.66 B$     |

*   **Analysis:** EPS and Revenue have shown fluctuations with recent quarters showing higher numbers, indicating growth.
| Date       | Revenue      | Profit Margin |
|------------|--------------|---------------|
| 2025-09-30 | $17.28B     | 77.69%       |
| 2025-06-30 | $15.81B     | 77.50%       |
| 2025-03-31 | $15.53B     | 77.98%       |
| 2024-12-31 | $15.62B     | 75.50%       |
| 2024-09-30 | $16.66B     | 75.51%       |

*   **Analysis:** Revenue and profit margin have been good.
| Date       | Equity      | ROE          |
|------------|--------------|---------------|
| 2025-09-30 | $51.85B     | 11.16%       |
| 2025-06-30 | $48.99B     | 9.04%       |
| 2025-03-31 | $48.34B     | 10.51%       |
| 2024-12-31 | $46.31B     | 8.08%       |
| 2024-09-30 | $44.50B     | 7.09%       |

*   **Analysis:** Equity and ROE have shown a good track record.

**7) Comprehensive Analysis (Summary):**

*   **Overall Assessment:** MRK has underperformed the S&P 500 historically, but recent indicators suggest a potential for improvement.
*   **Strengths:**
    *   Positive analyst ratings.
    *   Recent increase in relative divergence.
    *   Relatively low Beta.
    *   Good EPS and Profit Margin numbers.
*   **Weaknesses:**
    *   Significant underperformance vs. the S&P 500.
    *   Overbought RSI.
    *   Negative Alpha in recent periods.
*   **Mixed Signals:**
    *   Mixed news headlines (positive and negative).
    *   MRI suggests Medium to High Investment while Expected Return is neutral.
*   **Investment Recommendation:** Cautiously optimistic. While MRK has strong fundamentals and a "Buy" rating, investors should be aware of the historical underperformance and overbought RSI. The upward target from Morgan Stanley along with good earnings are positive signals. A small portion in the portfolio would be reasonable.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.